| text only |
|
|||||||||||||||||||||||||||||
| Leadership Team | ||
Michael Boyd, M.D., Ph.D.
Abraham A. Mitchell Chair and Director Michael Boyd joined the USA Mitchell Cancer Institute in 2002 as Director. Under his leadership, the Institute has developed into the only academic cancer research and clinical program in the upper Gulf Coast region, with robust medical, surgical, gynecological and radiation oncology treatment services. Basic and translational research programs are also thriving in the areas of molecular pathology and diagnostics, metastasis and tumor biology, cell and immune therapies, prevention and drug discovery. His vision, which includes achieving competitiveness for the National Cancer Institute Comprehensive Cancer Center designation, resulted in the construction of a 125,000 square foot integrated research and clinical care facility that was completed in Fall 2008. Dr. Boyd obtained his M.D. and Ph.D. in Pharmacology and Organic Chemistry from Vanderbilt University. Prior to joining the Mitchell Cancer Institute, Dr. Boyd served in many distinguished positions at the National Cancer Institute including Chief of the Laboratory of Drug Discovery Research and Development and Director of the Molecular Targets Discovery Program. Dr. Boyd has introduced major innovations for anti-cancer and anti-HIV drug discovery research and development at the National Cancer Institute. Dr. Boyd and his colleagues subsequently interpreted a wide array of novel anti-HIV and anti-tumor drug development leads and candidates. His team’s discoveries are the basis of more than 130 U.S. and international patents and patents pending. Dr. Boyd has over 435 scientific publications to his credit. His research and public service have been recognized by numerous awards, including the U.S. Public Health Service Commendation and Meritorious Service Medals, the Achievement Award of the Society of Toxicology, two Pfizer Awards in Pharmacology, the Lupiloff Award in Clinical Oncology, and others. Eddie Reed, M.D. Clinical Director and Point Clear Charities Chair, Abraham Mitchell Distinguished Investigator and Professor of Oncologic Sciences Eddie Reed joined the USA Mitchell Cancer Institute in 2008 and serves as Clinical Director. Dr. Reed directs clinical programs and continues his research that concentrates on molecular pharmacology and clinical development of novel platinum compounds. His clinical focus is on ovarian cancer and metastatic prostate cancer. “I was attracted by the tremendous growth potential of the USA Mitchell Cancer Institute and Mobile, Alabama,” said Reed. “Cancer care is at its very best when you deliver cancer patients the latest in treatment options that are based on solid research. By combining state-of-the-art cancer care with state-of-the-art research, patient outcome is best.” Prior to his appointment at USA, Dr. Reed worked at the Centers for Disease Control (CDC) in Atlanta, where he served as Director of the Division of Cancer Prevention and Control. Dr. Reed earned his medical degree from Yale University, and then completed his internship and residency at Stanford University, followed by a medical oncology fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland. From 1985 to 2001, he served in a variety of increasingly responsible roles at NCI, including Senior Investigator, Chief of the NCI’s Medical Ovarian Cancer Section, and Chief of the Clinical Pharmacology Branch, Division of Cancer Treatment. At NCI, Reed achieved international recognition for his pioneering studies on clinical development of taxol for the treatment of ovarian cancer. In 2001, Reed moved to the University of West Virginia (UWVA) where he was appointed Director of the Mary Babb Randolf Cancer Center and in 2005, he was recruited to the CDC in Atlanta. Hung Khong, M.D.
Associate Director for Clinical Research and Assistant Professor of Oncologic Sciences Hung Khong joined the USA Mitchell Cancer Institute in 2003 as a medical oncologist and as head of the Clinical Immunotherapeutics Research Laboratory. In 2009, he was appointed Associate Director for Clinical Research. In this role, Dr. Khong oversees and expands the clinical trials program at the Mitchell Cancer Institute and continues his practice in medical oncology. Prior to joining the USA Mitchell Cancer Institute, Dr. Khong was a senior clinical fellow in the surgery branch of the National Cancer Institute located in Bethesda, Maryland. From 1997 to 2000, he was a clinical fellow in medical oncology in the medicine branch at NCI. Dr. Khong received his doctorate of medicine degree from Temple University School of Medicine in Philadelphia. He completed his residency in internal medicine at the Baylor College of Medicine in Houston. In 2000, Dr. Khong was awarded the NCI Center for Cancer Research Senior Fellowship Training Award, an extremely competitive three-year training grant presented to the most outstanding clinical fellows in the Center for Cancer Research at NCI. Laurie Owen, Ph.D.
Barbara Colle Chair and Associate Director, Basic and Translational Sciences and Professor of Oncologic Sciences Laurie Beth Owen joined the USA Mitchell Cancer Institute in fall 2008 as Associate Director for Basic and Translational Sciences. Dr. Owen is a nationally renowned cancer researcher, Mobile native and USA alumna. Dr. Owen has a renowned career in tumor immunology research, with multiple patents on her innovations used in cancer therapy. She received her Bachelor of Science degree in medical technology from the USA College of Allied Health Professions in 1980. In 1986, she earned her Ph.D. in microbiology/immunology from the University of Oklahoma Health Sciences Center, where she was awarded a Noble Foundation fellowship and received the University of Oklahoma Regent’s award for outstanding graduate research. After completing post-doctoral training at the University of Texas M.D. Anderson Cancer Center (UT-MDACC) as a Preuss Foundation fellow, she served as assistant and associate professor of immunology at UT-MDACC from 1990-2000. Owen held positions as professor of biomedical sciences at the University of California-Riverside and professor of immunology at the Beckman Research Institute, City of Hope in Pasadena, Calif., (2000-2003) before serving as founding Director of Research and Development at a privately-held biotechnology company, Biolegend, in San Diego. The company develops antibody reagents for medical research. Before joining USA, Owen was Director of Research, Development, and Enterprise Relations at the University of California-Riverside. The author of over 100 research articles, book chapters, and reports, her scientific contributions have been profiled in the Wall Street Journal, Newsweek, CNN Nightly News, and National Public Radio, among others. She has recently served as a member of the Board of Directors for the American Melanoma Foundation, and on the scientific advisory board for the University of Montana Health Sciences Institute, Signature Biosciences, and on the editorial board of the Journal of Interferon and Cytokine Biology, Apoptosis, and the Journal of Experimental Therapeutics. |
 Left to right: Dr. Eddie Reed, Dr. Laurie Owen, Dr. Hung Khong, Dr. Michael Boyd |
|
|
University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: October 27, 2009 3:46 PM http://www.southalabama.edu/mci/aboutleadership.html |
 |